NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 130 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.07 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $71,433 | -18.7% | 17,508 | 0.0% | 0.00% | – |
| Q4 2022 | $87,890 | -59.6% | 17,508 | +5.3% | 0.00% | – |
| Q3 2022 | $217,403 | -0.0% | 16,621 | -2.0% | 0.00% | – |
| Q2 2022 | $217,466 | -3.0% | 16,963 | +15.4% | 0.00% | – |
| Q1 2022 | $224,114 | -29.1% | 14,696 | -17.7% | 0.00% | – |
| Q4 2021 | $316,000 | -15.1% | 17,864 | +1.1% | 0.00% | – |
| Q3 2021 | $372,000 | -0.5% | 17,676 | -6.8% | 0.00% | – |
| Q2 2021 | $374,000 | -17.8% | 18,968 | +21.3% | 0.00% | – |
| Q1 2021 | $455,000 | -3.2% | 15,641 | +0.8% | 0.00% | – |
| Q4 2020 | $470,000 | +95.8% | 15,518 | +3.0% | 0.00% | – |
| Q3 2020 | $240,000 | -18.6% | 15,071 | 0.0% | 0.00% | – |
| Q2 2020 | $295,000 | +43.2% | 15,071 | -9.6% | 0.00% | – |
| Q1 2020 | $206,000 | – | 16,668 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |